Transplantation · 2012 · 27 citations · 41 references
Life SciencesImmunologyAdaptive ImmunityImmunoregulationTransplant ImmunologyAdaptive Immune ResponsesAllograft RejectionAntigen RecognitionCell-mediated ImmunityImmunological MemoryTransplant ImmunotherapyCytokine-mediated Effector ResponsesHeterologous ImmunityImmune Memory ResponsesIntegrin AntagonistsLymphocytic ChoriomeningitisMixed Lymphocyte ReactionPost-transplant ImmunosuppressionT Cell Cytokine Production
BACKGROUND: Recent evidence suggests that alloreactive memory T cells are generated by the process of heterologous immunity, whereby memory T cells arising in response to pathogen infection crossreact with donor antigens. Because of their diminished requirements for costimulation during recall, these pathogen-elicited allocrossreactive memory T cells are of particular clinical importance, especially given the emergence of costimulatory blockade as a transplant immunosuppression strategy. METHODS: We used an established model of heterologous immunity involving sequential infection of a naïve C57BL/6 recipient with lymphocytic choriomeningitis virus and vaccinia virus, followed by combined skin and bone marrow transplant from a BALB/c donor. RESULTS: We demonstrate that coupling the integrin antagonist anti-leukocyte functional antigen (LFA)-1 with costimulatory blockade could surmount the barrier posed by heterologous immunity in a fully allogeneic murine transplant system. The combined costimulatory and integrin blockade regimen suppressed proliferation of alloreactive memory T cells and attenuated their cytokine effector responses. This combined blockade regimen also promoted the retention of FoxP³⁺ Tregs in draining lymph nodes. Finally, we show that in an in vitro mixed lymphocyte reaction system using human T cells, the combination of belatacept and anti-LFA-1 was able to suppress cytokine production by alloreactive memory T cells that was resistant to belatacept alone. CONCLUSIONS: As an antagonist against human LFA-1 exists and has been used clinically to treat psoriasis, these findings have significant translational potential for future clinical transplant trials.
41
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
Christian P. Larsen, Eric T. Elwood, Diane Z. Alexander et al. · Nature · 1996 · 1.5K citations